1. Ferlay J, Soerjomataram I, Dikshit R, et al.: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359-386, 2015.
2. Katki HA, Kinney WK, Fetterman B, et al.: Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 12: 663-672, 2011.
3. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC and Wacholder S: Human papillomavirus and cervical cancer. Lancet 370: 890-907, 2007.
4. WHO: WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. . 2014.
5. Wright TC, Jr., Stoler MH, Behrens CM, Sharma A, Sharma K and Apple R: Interlaboratory variation in the performance of liquid-based cytology: insights from the ATHENA trial. Int J Cancer 134: 1835-1843, 2014.
6. Arbyn M, Roelens J, Simoens C, et al.: Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. Cochrane Database Syst Rev: CD008054, 2013.
7. Koliopoulos G, Nyaga VN, Santesso N, et al.: Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev 8: CD008587, 2017.
8. Seedorf K, Oltersdorf T, Krammer G and Rowekamp W: Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells. EMBO J 6: 139-144, 1987.
9. Trope A, Sjoborg K, Eskild A, et al.: Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia. J Clin Microbiol 47: 2458-2464, 2009.
10. Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B and Tommasino M: The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 40: 1-13, 2010.
11. McLaughlin-Drubin ME and Munger K: The human papillomavirus E7 oncoprotein. Virology 384: 335-344, 2009.
12. Sen P, Ganguly P and Ganguly N: Modulation of DNA methylation by human papillomavirus E6 and E7 oncoproteins in cervical cancer. Oncol Lett 15: 11-22, 2018.
13. Honegger A, Schilling D, Bastian S, et al.: Dependence of intracellular and exosomal microRNAs on viral E6/E7 oncogene expression in HPV-positive tumor cells. PLoS Pathog 11: e1004712, 2015.
14. Zhang R, Lu H, Lyu YY, et al.: E6/E7-P53-POU2F1-CTHRC1 axis promotes cervical cancer metastasis and activates Wnt/PCP pathway. Sci Rep 7: 44744, 2017.
15. zur Hausen H: Papillomaviruses in human cancer. Appl Pathol 5: 19-24, 1987.
16. Saslow D, Solomon D, Lawson HW, et al.: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 62: 147-172, 2012.
17. Wright TC, Jr., Stoler MH, Sharma A, Zhang G, Behrens C and Wright TL: Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol 136: 578-586, 2011.
18. Yali Yuan GH, Li Ma, et al.: Expression level and clinical value of HPV-16/18 E6 and E7 proteins in cervical intraepithelial lesion. Journal of China-Japan Friendship Hospital 32: 352-355, 2018.
19. Zhang L, Yang B, Zhang A, et al.: Association between human papillomavirus type 16 E6 and E7 variants with subsequent persistent infection and recurrence of cervical high-grade squamous intraepithelial lesion after conization. J Med Virol 88: 1982-1988, 2016.
20. Qiao YL, Jeronimo J, Zhao FH, et al.: Lower cost strategies for triage of human papillomavirus DNA-positive women. Int J Cancer 134: 2891-2901, 2014.
21. Zhang Q, Dong L, Hu S, et al.: Risk stratification and long-term risk prediction of E6 oncoprotein in a prospective screening cohort in China. Int J Cancer 141: 1110-1119, 2017.